University of Oxford joined Oxford Sciences Innovation to back neuromuscular disease therapy spinout PepGen, which will move its base to the US.

PrinterPrezz enticed the Berkeley Catalyst Fund in a series A round that will help expand its medical device 3D printing business.

Konruns Pharma came on board as Nuance closed a round that will fund the clinical progress of its small molecule anti-tumour drug candidate.

Novo returned to reinvest in the neuromuscular disorder therapy developer in a round that will fund the progress of its lead candidate through a phase 1 clinical trial.

Solvay Ventures was among the participants in a series A round for 3D-printed medical technology developer PrinterPrezz.

The digital medicine provider has closed a round led by SoftBank Vision Fund 2 that also featured Novartis, taking its total funding to at least $214m.

Heidelberg and Inserm have scored exits after an acquisition that followed MYR's chronic hepatitis delta virus treatment receiving European regulatory approval.

Alexandria Venture Investments has helped RNA drug developer Remix Therapeutics launch with seed and series A funding.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

The underwriters have taken up the over-allotment option in BMS and Celgene-backed oncology drug developer Silverback's initial public offering.